Project Grant R01AG103221
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- The National Institute on Aging awarded The Washington University $246,225 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop an ultrasensitive, multiplexed plasmonic-fluor-linked immunosorbent assay (P-FLISA) for quantitative measurement of plasma phosphorylated tau 217 (P-TAU217), amyloid-beta 42 (AB42), and amyloid-beta 40 (AB40) as neurological biomarkers for early Alzheimer's disease detection. The project will deliver two specific research aims. Aim 1...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging awarded The Washington University $129,876 under the Aging Research program (CFDA 93.866) on June 15, 2026, to investigate the relationship between tau accumulation, white matter degeneration, and cognition in preclinical Alzheimer disease. The funded research uses autosomal dominant Alzheimer disease (ADAD) cohorts enrolled in the Dominantly Inherited Alzheimer Network (DIAN) to examine how tau tangle accumulation and white matter microstructural damage precede...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded The Washington University $3,188,901 under the Aging Research program (CFDA 93.866) for a four-year project beginning September 1, 2025, and concluding August 31, 2029. This project grant supports research to map amyloid, tau, and neurodegeneration (ATN) biomarkers in relation to neuropsychiatric phenotypes and genotypes across the Alzheimer's disease continuum using machine learning methodologies. The research...
- The National Institute on Aging awarded The Washington University $150,114 on March 18, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of brain-engrafted monocyte-derived macrophages in Alzheimer's disease. The research examines how monocyte-derived macrophages infiltrating the brain contribute to Alzheimer's disease pathology. The F99 phase involves assessing the effects of promoting or depleting brain-engrafted monocyte-derived macrophages on amyloid plaque...
- The National Institute on Aging awarded a $9.563 million Cooperative Agreement to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to support the Dominantly Inherited Alzheimer Network (DIAN). DIAN will conduct longitudinal biomarker research and clinical studies focused on autosomal dominant Alzheimer's disease (ADAD). The network will validate the amyloid-tau-neurodegeneration (ATN) framework using plasma biomarkers across genetically and...
- The National Institute on Aging awarded The Washington University $1,366,056 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop a biocompatible fiber implant for long-term deep-brain imaging and manipulation in mouse models of Alzheimer disease. The implant integrates photoacoustic microscopy and two-photon microscopy for simultaneous functional and molecular imaging, along with microelectrode-based neural stimulation and microfluidics-based drug delivery to create a...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded the University of Washington $575,342 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop statistical and artificial intelligence tools that elucidate cognitive resilience in Alzheimer's disease by linking region-resolved neuropathology with cell-type programs, particularly microglia function. The project integrates quantitative digital neuropathology with single-cell and spatial molecular profiles to build methods that estimate...
- The National Institute on Aging awarded Brigham & Women's Hospital Inc. $751,786 on July 15, 2026, under the Aging Research program (CFDA 93.866) to identify genetic and plasma biomarkers that predict individual response to anti-amyloid-beta monoclonal antibody therapies for Alzheimer's disease. The project will investigate whether plasma biomarkers and microglia/astrocyte-specific polygenic Alzheimer's disease risk variants can predict amyloid-beta clearance, amyloid-related imaging...